Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 94

1.

Management of bone complications in patients with genitourinary malignancies.

Ballon-Landa E, Panian J, Derweesh IH, McKay RR.

Urol Oncol. 2019 Oct 29. pii: S1078-1439(19)30379-5. doi: 10.1016/j.urolonc.2019.09.028. [Epub ahead of print] Review.

PMID:
31676279
2.

Systemic Treatment of Bone Disease in Metastatic Urinary Malignancies.

Patel SH, Panian J, Bree K, Derweesh I, Millard F, Randall J, Mckay R.

Eur Urol Focus. 2020 Jan 15;6(1):17-25. doi: 10.1016/j.euf.2019.06.007. Epub 2019 Jun 27. Review.

PMID:
31255618
3.

Clinical benefit of early treatment with bone-modifying agents for preventing skeletal-related events in patients with genitourinary cancer with bone metastasis: A multi-institutional retrospective study.

Owari T, Miyake M, Nakai Y, Hori S, Tomizawa M, Ichikawa K, Shimizu T, Iida K, Samma S, Iemura Y, Momose H, Omori C, Otani T, Kuwada M, Hirao S, Oyama N, Nakagawa Y, Hayashi Y, Tanaka N, Fujimoto K.

Int J Urol. 2019 Jun;26(6):630-637. doi: 10.1111/iju.13939. Epub 2019 Mar 18.

PMID:
30883931
4.
5.

New and emerging therapies for bone metastases in genitourinary cancers.

Saylor PJ, Armstrong AJ, Fizazi K, Freedland S, Saad F, Smith MR, Tombal B, Pienta K.

Eur Urol. 2013 Feb;63(2):309-20. doi: 10.1016/j.eururo.2012.10.007. Epub 2012 Nov 23. Review.

7.

Bisphosphonates for breast cancer.

Pavlakis N, Schmidt R, Stockler M.

Cochrane Database Syst Rev. 2005 Jul 20;(3):CD003474. Review. Update in: Cochrane Database Syst Rev. 2012;2:CD003474.

PMID:
16034900
8.

Burden of metastatic bone disease from genitourinary malignancies.

Mulders PF, Abrahamsson PA, Bukowski RM.

Expert Rev Anticancer Ther. 2010 Nov;10(11):1721-33. doi: 10.1586/era.10.136. Review.

PMID:
21080800
9.
10.

Bone-targeted agents: preventing skeletal complications in prostate cancer.

Morgans AK, Smith MR.

Urol Clin North Am. 2012 Nov;39(4):533-46. doi: 10.1016/j.ucl.2012.07.009. Epub 2012 Sep 4. Review.

11.

Zoledronic acid in genitourinary cancer.

Climent MA, Anido U, Méndez-Vidal MJ, Puente J.

Clin Transl Oncol. 2013 Nov;15(11):871-8. doi: 10.1007/s12094-013-1033-1. Epub 2013 Apr 25. Review.

PMID:
23615978
12.

Optimizing bone health and minimizing skeletal morbidity in men with prostate cancer.

McKay RR, Taplin ME, Choueiri TK.

Hematol Oncol Clin North Am. 2013 Dec;27(6):1261-83, ix. doi: 10.1016/j.hoc.2013.08.009. Epub 2013 Sep 20. Review.

13.

Toxicities following treatment with bisphosphonates and receptor activator of nuclear factor-κB ligand inhibitors in patients with advanced prostate cancer.

Gartrell BA, Coleman RE, Fizazi K, Miller K, Saad F, Sternberg CN, Galsky MD.

Eur Urol. 2014 Feb;65(2):278-86. doi: 10.1016/j.eururo.2013.05.015. Epub 2013 May 13. Review.

14.

Rationale for zoledronic acid therapy in men with hormone-sensitive prostate cancer with or without bone metastasis.

Saad F, McKiernan J, Eastham J.

Urol Oncol. 2006 Jan-Feb;24(1):4-12. Review.

PMID:
16414486
15.

Skeletal metastasis in renal cell carcinoma: A review.

Umer M, Mohib Y, Atif M, Nazim M.

Ann Med Surg (Lond). 2018 Jan 31;27:9-16. doi: 10.1016/j.amsu.2018.01.002. eCollection 2018 Mar. Review.

16.

Skeletal morbidity in men with prostate cancer: quality-of-life considerations throughout the continuum of care.

Saad F, Olsson C, Schulman CC.

Eur Urol. 2004 Dec;46(6):731-39; discussion 739-40. Review.

PMID:
15548440
17.

Managing bone metastases and reducing skeletal related events in prostate cancer.

Gartrell BA, Saad F.

Nat Rev Clin Oncol. 2014 Jun;11(6):335-45. doi: 10.1038/nrclinonc.2014.70. Epub 2014 May 13. Review. Erratum in: Nat Rev Clin Oncol. 2015 Jan;12(1). doi:10.1038/nrclinonc.2014.70.

PMID:
24821212
18.

Denosumab for the prevention of skeletal-related events in patients with bone metastasis from solid tumor.

Iranikhah M, Wilborn TW, Wensel TM, Ferrell JB.

Pharmacotherapy. 2012 Mar;32(3):274-84. doi: 10.1002/j.1875-9114.2011.01092.x. Epub 2012 Feb 13. Review.

PMID:
22392458
19.

Bisphosphonates for advanced prostate cancer.

Macherey S, Monsef I, Jahn F, Jordan K, Yuen KK, Heidenreich A, Skoetz N.

Cochrane Database Syst Rev. 2017 Dec 26;12:CD006250. doi: 10.1002/14651858.CD006250.pub2. Review.

20.

Bone health in men with prostate cancer: diagnostic and therapeutic considerations.

Saad F, Perrotte P, Bénard F, McCormack M, Karakiewicz PI.

Can J Urol. 2005 Jun;12 Suppl 2:9-15. Review.

PMID:
16018826

Supplemental Content

Support Center